PP
SKYE icon

PFS Partners’s Skye Bioscience SKYE Stock Holding History

PFS Partners’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Hold
1
– – ﹤0.01% 590
2025
Q4 		$1 Hold
1
– – ﹤0.01% 591
2025
Q3 		$4 Hold
1
– – ﹤0.01% 561
2025
Q2 		$5 Hold
1
– – ﹤0.01% 506
2025
Q1 		$2 Hold
1
– – ﹤0.01% 440
2024
Q4 		$3 Hold
1
– – ﹤0.01% 445
2024
Q3 		$4 Hold
1
– – ﹤0.01% 448
2024
Q2 		$9 Buy
+1
New +$12 ﹤0.01% 439

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS Partners's SKYE Position: Q1 2026 in Review

PFS Partners held its Skye Bioscience (SKYE) position steady in Q1 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #590.

PFS Partners first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $9 in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • PFS Partners held 1 share of Skye Bioscience worth $1 as of Q1 2026.
  • PFS Partners left its Skye Bioscience share count unchanged in Q1 2026.
  • Skye Bioscience made up ﹤0.01% of PFS Partners's portfolio in Q1 2026, its #590 holding.
  • PFS Partners first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • PFS Partners's Skye Bioscience position peaked at $9 in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on PFS Partners's 13F filing for Q1 2026, filed 9 Apr 2026.